Release details

2017-04-21 08:00 CEST
  • Print
  • Share Share
en

PCI Biotech: Presentation of fimaChem Phase I data in bile duct cancer at The International Liver Congress 2017

Oslo, Norway, April 21, 2017 PCI Biotech (OSE:PCIB), a clinical-stage company developing innovative therapeutics that address significant unmet medical needs, today announced that a poster of the fimaChem technology will be presented at the International Liver Congress 2017 - the annual meeting of the European Association for the Study of the Liver (EASL).

The event is taking place in Amsterdam, the Netherlands, from 19 to 23 April 2017, and Dr. Richard Sturgess, Coordinating Investigator of PCI Biotech's phase I study in inoperable bile duct cancer, will present the fimaChem poster on 21 April 2017.  The poster is named "Phase I study with Photochemical Internalisation (PCI) - A novel technology for treatment of perihilar cholangiocarcinoma" and includes a brief technology and method background and results from the recent fimaChem phase I study.

The results include an update on interim average overall survival data of 14.5 months per end March 2017, with 25% of the patients still being alive. Patients are on PCI Biotech's phase I study in inoperable extrahepatic bile duct cancer for six months, and thereafter followed for survival only.

The median overall survival (OS) in the studies that established gemcitabine and cisplatin as standard treatment in cholangiocarcinoma (CCA) was 11.7 and 11.2 months respectively (Valle et al. NEJM (2010) 362:1273-81 and Okusaka et al. BJC (2010) 103:469-74). These results may however not be directly comparable to the data in the fimaChem phase I study, as these studies include a wide range of different inoperable CCA patients, while the fimaChem phase I study focuses on inoperable perihilar CCA patients.

About PCI Biotech         
PCI Biotech is a biopharmaceutical company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform.  PCI is applied to three distinct anticancer paradigms: fimaChem (enhancement of chemotherapeutics for localised treatment of cancer), fimaVacc (T-cell induction technology for therapeutic vaccination), and fimaNAc (nucleic acid therapeutics delivery).

Photochemical internalisation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The company's lead fimaChem programme consists of a clinical Phase I/II clinical study in bile duct cancer, an orphan indication with a high unmet need and without approved products. fimaVacc applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies. fimaNAc utilises the endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and siRNA therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.

Contact information:   
PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo, Norway. www.pcibiotech.com      
Per Walday, CEO, pw@pcibiotech.com , Mobile: +47 917 93 429

This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.

HUG#2097270